TR201820076T4 - İlaç kombinasyonlarının salımı. - Google Patents
İlaç kombinasyonlarının salımı. Download PDFInfo
- Publication number
- TR201820076T4 TR201820076T4 TR2018/20076T TR201820076T TR201820076T4 TR 201820076 T4 TR201820076 T4 TR 201820076T4 TR 2018/20076 T TR2018/20076 T TR 2018/20076T TR 201820076 T TR201820076 T TR 201820076T TR 201820076 T4 TR201820076 T4 TR 201820076T4
- Authority
- TR
- Turkey
- Prior art keywords
- doxorubicin
- microspheres
- irinotecan
- ibuprofen
- polymer matrix
- Prior art date
Links
- 239000000890 drug combination Substances 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 6
- 239000004005 microsphere Substances 0.000 abstract 4
- 229960004679 doxorubicin Drugs 0.000 abstract 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 229960001680 ibuprofen Drugs 0.000 abstract 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 2
- 229960004768 irinotecan Drugs 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000010109 chemoembolization Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0716003A GB0716003D0 (en) | 2007-08-16 | 2007-08-16 | Delivery of drug combinations |
| EP07121158 | 2007-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201820076T4 true TR201820076T4 (tr) | 2019-01-21 |
Family
ID=39941549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/20076T TR201820076T4 (tr) | 2007-08-16 | 2008-08-18 | İlaç kombinasyonlarının salımı. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110229572A1 (enExample) |
| EP (1) | EP2190409B9 (enExample) |
| JP (3) | JP2010536738A (enExample) |
| ES (1) | ES2706023T3 (enExample) |
| TR (1) | TR201820076T4 (enExample) |
| WO (1) | WO2009022190A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1985286A1 (en) * | 2007-04-24 | 2008-10-29 | Biocompatibles UK Limited | Microspheres for treatment of brain tumours |
| EP2771034B1 (en) * | 2011-10-25 | 2018-08-08 | Nektar Therapeutics | Topoisomerase-i and-ii inhibitors for use in the treatment of patients suffering from cancer |
| CN106456631A (zh) * | 2014-03-06 | 2017-02-22 | 南加利福尼亚大学 | 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用 |
| US20200397766A1 (en) * | 2018-02-23 | 2020-12-24 | Van Rijn Beheer B.V. | Porous embolization microspheres comprising drugs |
| WO2020077170A1 (en) | 2018-10-12 | 2020-04-16 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Small polymeric carriers for delivery of agents |
| CN110327300B (zh) * | 2019-07-23 | 2020-08-07 | 赵修文 | 一种负载药物的聚乙烯醇微球 |
| WO2022010850A1 (en) * | 2020-07-06 | 2022-01-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Polymeric carriers for delivery of therapeutic agents |
| WO2022047544A1 (en) * | 2020-09-04 | 2022-03-10 | IP Cornerstone Pty Ltd | Minimally invasive treatment of osteoarthritis and other conditions |
| CN117677388A (zh) * | 2021-05-12 | 2024-03-08 | 润新生物公司 | 某些化学实体、组合物和方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2762140B1 (en) * | 2001-02-19 | 2017-03-22 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| WO2003028696A2 (en) * | 2001-10-03 | 2003-04-10 | Celator Technologies Inc. | Compositions for delivery of drug combinations |
| US20050220880A1 (en) * | 2002-03-07 | 2005-10-06 | Lewis Andrew L | Drug carriers comprising amphiphilic block copolymers |
| US20040161466A1 (en) * | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
| DE602004014101D1 (de) * | 2003-02-12 | 2008-07-10 | Biocompatibles Uk Ltd | Zusammensetzungen für die chemoembolotherapie solider tumoren |
| US20040265368A1 (en) * | 2003-04-02 | 2004-12-30 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| EP1796644B1 (en) * | 2004-09-07 | 2011-04-13 | Biocompatibles UK Limited | Drug delivery from embolic agents |
| US8663673B2 (en) * | 2005-07-29 | 2014-03-04 | Surmodics, Inc. | Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility |
-
2008
- 2008-08-18 WO PCT/GB2008/050722 patent/WO2009022190A1/en not_active Ceased
- 2008-08-18 TR TR2018/20076T patent/TR201820076T4/tr unknown
- 2008-08-18 JP JP2010520637A patent/JP2010536738A/ja active Pending
- 2008-08-18 ES ES08788693T patent/ES2706023T3/es active Active
- 2008-08-18 EP EP08788693.3A patent/EP2190409B9/en not_active Not-in-force
- 2008-08-18 US US12/672,031 patent/US20110229572A1/en not_active Abandoned
-
2014
- 2014-01-30 JP JP2014016185A patent/JP2014114307A/ja active Pending
-
2016
- 2016-06-08 JP JP2016114725A patent/JP2016216465A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110229572A1 (en) | 2011-09-22 |
| WO2009022190A1 (en) | 2009-02-19 |
| JP2010536738A (ja) | 2010-12-02 |
| JP2016216465A (ja) | 2016-12-22 |
| ES2706023T3 (es) | 2019-03-27 |
| JP2014114307A (ja) | 2014-06-26 |
| EP2190409B1 (en) | 2018-10-24 |
| EP2190409B9 (en) | 2019-03-06 |
| EP2190409A1 (en) | 2010-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201820076T4 (tr) | İlaç kombinasyonlarının salımı. | |
| Anjani et al. | Soluplus®-based dissolving microarray patches loaded with colchicine: Towards a minimally invasive treatment and management of gout | |
| NZ601200A (en) | Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) | |
| BR112015000320A2 (pt) | composições farmacêuticas dissuasivas de abuso, de liberação prolongada | |
| BR112013016772B8 (pt) | compostos, uso do composto e composição farmacêutica | |
| JP2008519047A5 (enExample) | ||
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| BRPI0507683A8 (pt) | dose unitária de formulação farmacêutica com liberação controlada, seu processo de preparação e uso de um copolímero de poli(acrilato de etila, metacrilato de metila) neutro | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| BRPI0910746B8 (pt) | agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica | |
| BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
| BRPI0911442A2 (pt) | conjugados potentes e ligantes hidrofílicos | |
| BRPI0819719B8 (pt) | compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo | |
| ZA200900929B (en) | Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same | |
| AR082691A1 (es) | Terapia de combinacion, producto farmaceutico, kit y uso | |
| WO2009001099A3 (en) | A pharmaceutical composition comprising polyaphron dispersion | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| WO2006089114A3 (en) | Methods and compositions for treating an anthrax toxin mediated condition | |
| WO2010073126A3 (en) | Compounds useful in delivering anti-neoplastic therapy and diagnostic imaging to hypoxic cells and methods of use thereof | |
| PL1962815T3 (pl) | Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne | |
| WO2012172433A3 (en) | A sustained -release composition containing a melanocortin receptor ligand as the active ingredient | |
| TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
| WO2006041538A3 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
| MX2009003815A (es) | Formulaciones farmaceuticas. | |
| JP2008541745A5 (enExample) |